Articles

News

Rift Valley Fever workshop summary

published in Vaccine, Volume 54, 30 April 2025

In June 2024, CEPI convened a workshop in Nairobi, Kenya, to discuss epidemiology and modeling for human RVF vaccine development, bringing together representatives from RVF-endemic countries, global collaborators, and international health organizations. This paper summarizes the workshop discussions and priorities. Read more

African Vaccine Manufacturing Supply Chain Forum 2024 – actions delivery update

Africa CDC and CEPI update on mitigations to address assessed African input material supply chain challenges

The African Union has set an ambitious goal: by 2040 over 60% of the vaccines needed for Africa’s population should be produced locally. A sustainable supply chain for the specialized input materials that go into making vaccines will be required Read more

First WHO International Standard for assessing Marburg vaccines’ responses now available

Use of the IS will harmonize how different laboratories assess the strength and duration of immune responses generated by Marburg virus vaccine candidates

This effort was funded by the National Institutes of Health, National Institutes of Allergy and Infectious Diseases, and CEPI. Data generated from using the Standard will help to inform current vaccine development and deployment strategies. Read more

CEPI launches the Pandemic Preparedness & Response Playbook

In collaboration with TGHN this playbook was created to bring together the many tools, resources and materials generated for pandemic preparedness and response before, during and after the COVID-19 pandemic

This information is shared in a variety of locations and formats, including individually published papers, websites, and conference presentations. The Playbook is being created to enable access to these learnings in a single location. The Regulatory Chapter is now available… Read more

CEPI has launched the Research Preparedness Program (RPP)

The RPP will support both advanced-stage clinical development of CEPI’s portfolio vaccines against priority diseases and the 100 Days Mission

The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more

Older News Here |